Risk of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C virus infection in people with HIV.

Open Access CRIS of the University of Bern 2026 Open access

Read full text
Authors: van Santen, Daniela K, Chalouni, Mathieu, Berenguer, Juan, Jarrin, Inmaculada, Miro, José M, Klein, Marina B, Young, Jim, Torgersen, Jessie, Rentsch, Christopher T, Gill, Michael J, Epstein, Rachel L, Nunes, David
+17 more Surial, Bernard, Rauch, Andri, Touloumi, Giota, Papadopoulos, Antonios, Wittkop, Linda, Gilbert, Camille, Leleux, Olivier, van der Valk, Marc, Boyd, Anders, Monforte, Antonella d'Arminio, Puoti, Massimo, Zangerle, Robert, Gisinger, Martin, Logan, Roger W, Rein, Sophia, Hernán, Miguel A, Lodi, Sara
DOI: 10.48620/92525
Cited by: 0

Abstract

Background To inform hepatocellular carcinoma (HCC) surveillance after hepatitis C virus (HCV) cure with direct-acting antivirals (DAA), we estimated HCC risk post-DAA in people with HIV with advanced liver fibrosis or cirrhosis under universal DAA.Methods We used data from HepCAUSAL, a collaboration of cohorts of HIV-HCV co-infection from Europe and North America. Eligibility criteria were HIV-HCV co-infection, advanced liver fibrosis or cirrhosis, DAA naïve, HIV-RNA

Fields of Study & Subjects

Hepatitis C virus research Hepatocellular Carcinoma Treatment and Prognosis Hepatitis B Virus Studies

Publication details

Journal / source
Open Access CRIS of the University of Bern
Publication date
20 May 2026
Language
EN